List of Excipients in Branded Drug ANTIVERT

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Casper Pharma LLC	ANTIVERT	meclizine hcl	70199-002	ALCOHOL
Casper Pharma LLC	ANTIVERT	meclizine hcl	70199-002	ANHYDROUS DIBASIC CALCIUM PHOSPHATE
Casper Pharma LLC	ANTIVERT	meclizine hcl	70199-002	FD&C BLUE NO. 1
Casper Pharma LLC	ANTIVERT	meclizine hcl	70199-002	MAGNESIUM STEARATE
Casper Pharma LLC	ANTIVERT	meclizine hcl	70199-002	POLYETHYLENE GLYCOL
Casper Pharma LLC	ANTIVERT	meclizine hcl	70199-002	STARCH, CORN

Antivert Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: August 9, 2026

Antivert is the brand name for meclizine hydrochloride, an oral antihistamine approved in the United States for nausea, vomiting, and dizziness associated with motion sickness, and for vertigo associated with diseases affecting the vestibular system.[1] The product has limited remaining exclusivity value because meclizine is an old, genericized active pharmaceutical ingredient. Commercial opportunity is concentrated in differentiated dosage forms, improved palatability, pediatric usability, lower-sedation positioning, and reliable supply of compliant excipients.

The strongest strategy is not a conventional generic tablet. A differentiated meclizine product could target chewable, orally disintegrating, orally dissolving, liquid, or low-sugar formats, subject to FDA regulatory and clinical requirements. Excipient selection must address meclizine’s bitter taste, tablet disintegration, moisture sensitivity, content uniformity at low strengths, and consumer demand for convenient motion-sickness dosing.

What is Antivert and what FDA products contain meclizine?

Antivert contains meclizine hydrochloride, an H1 antihistamine with anticholinergic activity. The product is marketed as oral tablets in multiple strengths, including 12.5 mg, 25 mg, and 50 mg presentations in U.S. labeling.[1]

Product attribute	Antivert position
Brand	Antivert
Active ingredient	Meclizine hydrochloride
Drug class	H1 antihistamine; antiemetic; vestibular suppressant
Primary uses	Motion sickness and vertigo
Dosage form	Oral tablet
U.S. regulatory status	FDA-approved prescription product; meclizine is also widely available through generic products
Reference product status	Antivert labeling exists, but commercial availability and marketing status may vary by strength and distributor
Biosimilar relevance	None; meclizine is a synthetic small molecule
Main commercial competitors	Generic meclizine tablets, chewable meclizine products, dimenhydrinate, diphenhydramine, and non-drug motion-sickness products

Meclizine products are commonly sold in 12.5 mg, 25 mg, and 50 mg strengths. Lower-strength products are relevant to pediatric and dose-titration strategies, although pediatric use must follow approved labeling and clinical guidance.

What excipients are used in Antivert tablets?

The Antivert label identifies conventional tablet excipients, including dibasic calcium phosphate, corn starch, magnesium stearate, and povidone, depending on the product presentation and manufacturer labeling.[1] Exact excipient composition should be confirmed against the current product-specific label because formulations can vary by strength, site, manufacturer, and packaging configuration.

These excipients support a conventional immediate-release tablet:

Excipient function	Representative excipient	Strategic role
Diluent	Dibasic calcium phosphate	Adds tablet mass and improves compressibility
Disintegrant	Corn starch	Promotes tablet breakup after administration
Binder	Povidone	Improves granule and tablet strength
Lubricant	Magnesium stearate	Reduces sticking and ejection force
Taste and appearance	Film-coating or color systems, where used	Improves swallowability, identification, and consumer acceptance

The existing excipient approach is low-cost and conventional. It is suitable for a standard immediate-release tablet but does not create meaningful product differentiation. Its commercial advantage is manufacturing familiarity rather than technical exclusivity.

What excipient problems matter most for meclizine products?

Bitter taste and oral acceptability

Meclizine hydrochloride can produce a bitter taste, which is a major barrier for chewable, orally disintegrating, and pediatric products. Taste masking should be treated as a core product-development issue rather than a cosmetic improvement.

Potential approaches include:

• Polymer-film coating of meclizine particles
• Lipid or wax-based coating
• Ion-exchange resin complexes
• Cyclodextrin inclusion complexes
• pH-modified granules
• Sweetener and flavor systems
• Multiparticulate capsules or sachets
• Press-coated or rapidly dispersible granules

Ion-exchange resins and polymer barriers can reduce immediate drug release in the mouth while preserving release in the gastrointestinal tract. The formulation must demonstrate acceptable dissolution under FDA conditions and avoid delayed or incomplete systemic exposure.

Low-dose content uniformity

The 12.5 mg strength creates greater risk of blend segregation and content-uniformity failure than higher-strength tablets. Excipient particle size, density, flow, and blending order should be controlled to limit stratification during tablet compression and filling.

Direct compression may be commercially attractive, but wet granulation can provide improved content uniformity and flow if the formulation has poor powder handling characteristics. Excessive lubricant exposure, especially magnesium stearate, can reduce tablet hardness and slow dissolution.

Moisture and physical stability

Orally disintegrating and chewable formats often use porous or highly water-soluble excipients. These systems can be more sensitive to humidity, tablet friability, and packaging conditions than conventional compressed tablets.

Candidate excipients include:

• Mannitol for cooling mouthfeel and low hygroscopicity
• Microcrystalline cellulose for structure
• Crospovidone for rapid water uptake
• Croscarmellose sodium for swelling-driven disintegration
• Low-substituted hydroxypropyl cellulose for rapid breakup
• Colloidal silicon dioxide for flow improvement
• Sucralose, aspartame, or acesulfame potassium for sweetness, subject to product positioning
• Maltitol or isomalt for sugar-reduced chewable systems

Aluminum-aluminum blister packaging, high-barrier cold-form foil, or desiccant-enabled bottles may be required for moisture-sensitive products. Packaging is part of the excipient strategy because a fast-disintegrating tablet can lose performance during shelf life if moisture uptake changes hardness or disintegration time.

Sedation and anticholinergic effects

Excipient changes cannot remove meclizine’s pharmacologic sedation or anticholinergic activity. A formulation may improve onset, swallowability, and adherence, but it should not be marketed as non-sedating without clinical evidence.

A lower-dose or dose-flexible product could support consumer and clinician interest in minimizing exposure. That strategy requires appropriate labeling and may involve a new drug application, an abbreviated new drug application, or another FDA pathway depending on the product’s relationship to an approved reference product.

What formulations are protected by Antivert patents?

Antivert has limited current patent leverage. Meclizine hydrochloride was developed and approved decades ago, and core compound and conventional immediate-release tablet patents would generally have expired long ago. Publicly available product information does not indicate a meaningful current patent barrier around the basic Antivert tablet.

IP category	Commercial assessment
Meclizine compound patent	Expected to be expired
Conventional immediate-release tablet	Expected to be unprotected by enforceable pioneer patent rights
Basic salt form	Expected to be mature and broadly available
Standard excipient system	Generally difficult to protect broadly
New taste-masked formulation	Potentially patentable if technically differentiated and non-obvious
Orally disintegrating tablet	Potentially patentable through composition, process, or performance limitations
Long-acting formulation	Potentially patentable, but requires clinical and pharmacokinetic support
Pediatric liquid or chewable	Potentially patentable if the formulation has a novel, non-obvious technical solution
Manufacturing process	Potentially protectable if it produces a defined quality or performance advantage
Packaging system	Potentially protectable, but usually narrower than formulation claims

Patent value would come from specific formulation architecture, not from the meclizine molecule. Useful claim limitations could include particle coating thickness, resin-drug ratio, dissolution profile, disintegration time, taste-masking performance, moisture uptake, or a defined excipient combination.

When does Antivert lose exclusivity?

Antivert’s principal market exclusivity has already expired. Generic meclizine products are widely available, and the market does not depend on an active brand patent to maintain pricing power.

Orange Book status

The FDA Orange Book identifies approved drug products and certain patent and exclusivity information. A sponsor evaluating an Antivert-related product should review current Orange Book entries, approved labeling, and any listed patents associated with the specific reference product.[2]

For a mature meclizine product, the relevant commercial question is usually not whether the original Antivert patent remains enforceable. It is whether a proposed product can obtain approval with an acceptable bioequivalence package and compete against low-cost generic products.

Paragraph IV challenges

A Paragraph IV certification would be relevant only if an applicable patent were listed for the reference product. For the basic Antivert immediate-release tablet, the primary competitive issue is likely generic price pressure rather than an active patent dispute.

A sponsor pursuing a new formulation may instead create its own patent estate. That estate could later affect follow-on products, but a formulation patent is not automatically a barrier to all generic meclizine products.

What FDA regulatory pathways apply to new Antivert formulations?

The regulatory pathway depends on whether the product is a direct generic equivalent or a differentiated formulation.

Development objective	Likely pathway	Key requirements
Conventional meclizine tablet equivalent	ANDA	Pharmaceutical equivalence, bioequivalence, quality, labeling
New strength or formulation with clinical differentiation	NDA or 505(b)(2) NDA	CMC, safety, efficacy or bridging data, labeling
Chewable or orally disintegrating product	ANDA or 505(b)(2), depending on reference relationship	Dissolution, bioequivalence, palatability and usability considerations
Pediatric liquid	ANDA or 505(b)(2)	Stability, dosing accuracy, preservative control, microbiological quality
Combination product	NDA or suitable abbreviated pathway	Combination justification, compatibility, clinical and CMC data

A 505(b)(2) application may be commercially useful where the sponsor relies partly on existing FDA findings for meclizine but introduces a new dosage form, route, strength, formulation, or dosing concept. The pathway does not eliminate the need to establish product-specific safety and efficacy where the change affects clinical performance.

What commercial opportunities exist for Antivert excipient innovation?

Orally disintegrating and orally dissolving tablets

A fast-disintegrating tablet could address travelers who cannot swallow tablets during motion sickness. The main technical targets are:

• Disintegration in less than one minute
• Acceptable mouthfeel
• Low friability
• Taste masking
• Moisture protection
• Adequate mechanical strength for distribution

Mannitol, crospovidone, and microcrystalline cellulose are common starting points, but the commercial value would depend on demonstrated taste and handling advantages.

Chewable tablets

Chewables are a strong fit for motion-sickness use because consumers may prefer a product that can be taken without water. The major challenges are bitterness, tablet size, texture, and dose flexibility.

A chewable product could use mannitol, isomalt, maltitol, or xylitol, combined with a coated meclizine intermediate. Sugar-free positioning may expand use among adults managing sugar intake, but polyol levels must be controlled to avoid gastrointestinal intolerance.

Pediatric liquid

A liquid could support patients who cannot swallow tablets. The formulation would need:

• Accurate dosing across age and weight ranges
• Chemical and microbiological stability
• Preservative compatibility
• Low sedimentation or controlled redispersibility
• Taste masking
• Child-resistant packaging
• Dosing syringe compatibility

The pediatric market is commercially attractive but regulatory-sensitive. Meclizine’s sedating and anticholinergic effects require careful labeling and responsible dosing communication.

Low-dose and dose-flexible products

A 12.5 mg product may support dose adjustment and lower-exposure use. A scored tablet, mini-tablet, or multiparticulate capsule could improve dosing flexibility. The business case depends on whether the format earns a price premium in a market with inexpensive generic tablets.

Travel and convenience packaging

Unit-dose blister packs, pocket-sized packaging, and moisture-resistant formats could create a retail advantage. Packaging patents would be secondary to formulation patents, but a combination of taste masking, rapid disintegration, and travel packaging could support a differentiated brand.

How does Antivert compare with competing motion-sickness drugs?

Product	Active ingredient	Common dosage forms	Differentiation pressure
Antivert	Meclizine hydrochloride	Tablets, chewables, other generic forms	Long duration and established use; sedation remains a limitation
Dramamine	Dimenhydrinate	Tablets, chewables, liquids	Strong consumer recognition; frequent dosing and sedation concerns
Bonine	Meclizine	Chewable tablets	Direct brand competition in motion sickness
Diphenhydramine products	Diphenhydramine	Tablets, capsules, liquids	Low cost; stronger sedation and anticholinergic burden
Scopolamine transdermal	Scopolamine	Patch	Longer duration; prescription, transdermal, and anticholinergic constraints
Non-drug products	Various	Wristbands and devices	No systemic adverse effects; variable efficacy

Meclizine’s strongest commercial position is once-daily or less-frequent dosing relative to shorter-acting antihistamines. Its main weakness is that generic tablets are inexpensive and widely available. Excipient innovation must therefore produce a visible consumer benefit.

Which companies are challenging the Antivert market?

The market is fragmented among generic manufacturers, retail private-label suppliers, and branded motion-sickness companies. Generic competition includes manufacturers and distributors of meclizine hydrochloride tablets and chewable products. Brand competition includes the owners and licensees of Dramamine and Bonine products.

The main competitive threats are:

1. Low-cost generic meclizine tablets.
2. Chewable meclizine products with stronger consumer recognition.
3. Dimenhydrinate products with broad retail distribution.
4. Scopolamine patches for longer-duration travel.
5. Private-label products sold through pharmacies, supermarkets, and online retailers.

Public company-level market share and revenue data for Antivert specifically are limited. Antivert revenue should not be estimated from total meclizine-market sales without separating branded, generic, prescription, and over-the-counter channels.

What patent litigation and settlement risks affect Antivert?

No major current patent litigation or settlement agreement is central to the basic Antivert tablet market based on the mature status of meclizine. The material litigation risk would arise from a newly patented formulation or delivery system.

A sponsor developing a differentiated product should assess:

• Patentability of taste-masked particles
• Freedom to operate around resin complexes and polymer coatings
• Existing ODT and chewable formulation patents
• Claims covering dissolution and disintegration performance
• Patent term and regulatory exclusivity for any new application
• Potential induced-infringement theories tied to method-of-use labeling
• Settlement risk if a later generic challenges a formulation patent

Broad claims covering only "meclizine plus a pharmaceutically acceptable excipient" would face substantial validity risk. Narrow claims tied to reproducible performance data are more defensible.

How strong is the Antivert patent estate?

The legacy Antivert patent estate is weak as a barrier to generic entry. The active pharmaceutical ingredient is mature, conventional oral tablets are widely available, and the market has established generic substitution.

A new sponsor could build a moderate formulation estate if it combines:

• Composition claims
• Particle-coating claims
• Process claims
• Dissolution and disintegration limitations
• Packaging claims
• Method-of-use claims tied to a differentiated dosing regimen

The strongest protection would cover a product that is difficult to replicate while remaining commercially manufacturable. A simple excipient substitution is unlikely to support durable exclusivity.

What generic launch risks exist for a new Antivert formulation?

The main launch risk is price competition from existing meclizine products. Other risks include:

• Failure to show bioequivalence for a rapidly disintegrating formulation
• Taste-masking technology that delays drug release
• Poor tablet robustness during shipping
• Moisture-driven stability failures
• Inadequate dosing accuracy in liquid products
• Consumer confusion between meclizine, dimenhydrinate, and diphenhydramine
• Limited willingness to pay for a reformulated mature drug
• Patent claims that are too narrow to deter design-around
• Retail distribution costs exceeding the available price premium

The best commercial targets are products that solve a clear use problem: taking meclizine without water, masking bitterness, enabling precise low-dose administration, or improving travel portability.

What geographic opportunities exist for meclizine excipient products?

The United States offers a large established market but also the highest generic price pressure. Canada, Europe, Japan, and selected Latin American markets may offer opportunities for chewable, orally disintegrating, and pediatric presentations, but regulatory requirements, prescription status, and brand recognition differ by country.

Geographic expansion requires review of:

• Local approval status for meclizine
• Prescription versus over-the-counter classification
• Country-specific excipient restrictions
• Permitted sweeteners and colorants
• Pediatric labeling standards
• Local patent and supplementary protection rights
• Stability requirements for climate zones
• Packaging and language requirements

A global formulation should avoid excipients with uneven regulatory acceptance and should be tested under relevant International Council for Harmonisation stability conditions.

Key Takeaways

• Antivert is meclizine hydrochloride, an old and genericized antihistamine used for motion sickness and vertigo.
• The basic tablet has little remaining exclusivity value and limited patent-based protection against generic entry.
• Conventional excipients such as dibasic calcium phosphate, starch, povidone, and magnesium stearate support low-cost manufacturing but provide little differentiation.
• The most credible opportunities are taste-masked chewables, orally disintegrating tablets, pediatric liquids, low-dose formats, and travel-friendly unit-dose packaging.
• Meclizine’s bitterness, low-dose content uniformity, moisture sensitivity, and sedation profile are the principal development constraints.
• A defensible new patent estate should focus on measurable formulation performance and manufacturing controls, not broad excipient combinations.
• The commercial case depends on earning a price premium over generic tablets through convenience, palatability, and dosing flexibility.

FAQs

Can excipients make Antivert non-sedating?

No. Meclizine’s sedation is pharmacologic. Excipients can improve taste, disintegration, dosing, and adherence but do not remove the active ingredient’s central nervous system effects.

Is a meclizine orally disintegrating tablet eligible for an ANDA?

Possibly. Eligibility depends on the reference product, dosage-form equivalence, labeling, formulation, and FDA bioequivalence requirements. A materially different clinical profile may require a 505(b)(2) NDA rather than a conventional ANDA.

Which excipient is best for masking meclizine bitterness?

No single excipient is universally best. Polymer-coated particles, ion-exchange resin complexes, and lipid barriers are leading technical approaches. The preferred system depends on dissolution, stability, manufacturability, and sensory-testing results.

Can a company patent a new Antivert excipient combination?

Yes, but the claim must satisfy novelty, non-obviousness, written-description, enablement, and utility requirements. A routine substitution of one diluent or lubricant is unlikely to provide strong protection.

Does Antivert have biosimilar competition?

No. Biosimilar regulation applies to biological products. Meclizine is a synthetic small molecule, so competition occurs through generic-drug and differentiated-formulation pathways.

References

1. Pfizer Laboratories Division. (n.d.). Antivert (meclizine hydrochloride) tablets, USP: Prescribing information. DailyMed. https://dailymed.nlm.nih.gov/dailymed/

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, 44th edition. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files

3. U.S. Food and Drug Administration. (2024). Inactive ingredient database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm

4. U.S. Food and Drug Administration. (2024). ANDA submissions: Content and format. https://www.fda.gov/drugs/guidance-compliance-regulatory-information

5. U.S. Food and Drug Administration. (2024). 505(b)(2) applications. https://www.fda.gov/drugs/types-applications/abbreviated-new-drug-application-anda/505b2-applications